AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis

AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa. Yngvar P. Berg, CEO; [email protected] Astrid Hilde Myrset, Clinical Director; [email protected] April 2011

The release as fetched from its publisher. algipharma.com ↗